Patrick C May

US Patent:

56864760, Nov 11, 1997

Filed:

Mar 15, 1995

Appl. No.:

8/404700

Inventors:

Patrick C. May - Carmel IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31445

US Classification:

514324

Abstract:

This invention encompasses methods for the inhibition of Alzheimer's Disease comprising administering to a human in need thereof an effective amount of a compound of Formula I ##STR1## wherein R. sup. 1 and R. sup. 3 are independently hydrogen, --CH. sub. 3, ##STR2## wherein Ar is optionally substituted phenyl; R. sup. 2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof. The present invention also provides methods of increasing TGF-. beta. expression in the brain, comprising administering to a human in need thereof an effective amount of a compound of formula 1. The present invention also provides methods of inhibiting the. beta. -amyloid peptide mediated neurotoxicity or inflammatory response associated with Alzheimer's Disease (AD) comprising administering to a human in need thereof an effective amount of a compound of formula 1.

US Patent:

56522592, Jul 29, 1997

Filed:

May 9, 1996

Appl. No.:

8/645013

Inventors:

Patrick C. May - Carmel IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 3140

US Classification:

514422

Abstract:

This invention encompasses methods for the inhibition of Alzheimer's Disease comprising administering to a human in need thereof an effective amount of a compound of Formula I ##STR1## wherein R. sup. 1 and R. sup. 3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; R. sup. 2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof. The present invention also provides methods of increasing TGF-. beta. expression in the brain, comprising administering to a human in need thereof an effective amount of a compound of formula 1. The present invention also provides methods of inhibiting the. beta. -amyloid peptide mediated neurotoxicity or inflammatory response associated with Alzheimer's Disease (AD) comprising administering to a human in need thereof an effective amount of a compound of formula 1.

US Patent:

55524150, Sep 3, 1996

Filed:

Dec 21, 1993

Appl. No.:

8/171387

Inventors:

Patrick C. May - Carmel IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31445
A61K 3138

US Classification:

514324

Abstract:

This invention encompasses methods for the inhibition of Alzheimer's Disease comprising administering to a human in need thereof an effective amount of a compound of Formula I ##STR1## wherein R. sup. 1 and R. sup. 3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; R. sup. 2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof. The present invention also provides methods of increasing TGF-. beta. expression in the brain, comprising administering to a human in need thereof an effective amount of a compound of formula 1. The present invention also provides methods of inhibiting the. beta. -amyloid peptide mediated neurotoxicity or inflammatory response associated with Alzheimer's Disease (AD) comprising administering to a human in need thereof an effective amount of a compound of formula 1.

US Patent:

20190038613, Feb 7, 2019

Filed:

Mar 10, 2017

Appl. No.:

16/076889

Inventors:

- Indianapolis IN, US
Patrick Cornelius May - Fort Wayne IN, US

International Classification:

A61K 31/4439
A61P 25/28
A61K 39/395

Abstract:

The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of (1r, 1′R,4R)-4-methoxy-5″-methyl-6′-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3′H-dispiro[cyclohexane-1,2′-indene-1′,2″-imidazol]-4″-amine, or a pharmaceutically acceptable salt thereof (including the camsylate salt thereof); in combination with an effective amount of an anti-N3pGlu Abeta antibody.